Antifungal Activities of Fluconazole, Caspofungin (MK0991), and Anidulafungin (LY 303366) Alone and in Combination Against Candida Spp. And Crytococcus Neoformans via Time-Kill Methods

Diagn Microbiol Infect Dis. 2002 May;43(1):13-7. doi: 10.1016/s0732-8893(02)00361-9.


The activities of the echinocandins caspofungin and anidulafungin were evaluated alone and in combination with fluconazole using time-kill methods against isolates of Candida albicans, Candida glabrata, Candida tropicalis, Candida krusei, and Cryptococcus neoformans. Antifungal concentrations tested against each isolate were 0.5 microg/mL and 20 microg/mL of fluconazole and 0.007 microg/mL and 2 microg/mL of both caspofungin and anidulafungin. In addition, 20 microg/mL of fluconazole was tested with 2 microg/mL of caspofungin and anidulafungin to test for additive or antagonistic activity. Finally 0.5 microg/mL of fluconazole was tested with 0.007 microg/mL of caspofungin and anidulafungin to test for synergy. Combinations of fluconazole and caspofungin or anidulafungin resulted in indifference. Azole-echinocandin combinations do not produce antagonistic effects; therefore, combinations of these agents may warrant future clinical evaluation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anidulafungin
  • Anti-Bacterial Agents / pharmacology*
  • Antifungal Agents / pharmacology*
  • Candida / drug effects*
  • Caspofungin
  • Cell Division / drug effects
  • Cryptococcus neoformans / drug effects*
  • Drug Resistance, Multiple, Fungal
  • Drug Therapy, Combination
  • Echinocandins
  • Fluconazole / pharmacology*
  • Humans
  • Lipopeptides
  • Logistic Models
  • Microbial Sensitivity Tests
  • Peptides*
  • Peptides, Cyclic / pharmacology*
  • Time Factors


  • Anti-Bacterial Agents
  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides
  • Peptides, Cyclic
  • Fluconazole
  • Anidulafungin
  • Caspofungin